LONDON, UK: Oncimmune Holdings plc, a company that provides autoantibody profiling services to the pharma and biotech industry, has announced the appointment of Martin Gouldstone as its new Chief Executive Officer and Martin Hudson as its new Finance Director, as part of a leadership reshuffle.
Martin Gouldstone will join Oncimmune on 1 August 2023, replacing Dr Adam M Hill, who stepped down in June 2023 after the sale of Oncimmune Limited, the Company’s diagnostic business. Martin Gouldstone has over 25 years of experience in the life science sector, including senior roles at a major CRO and at Owkin Inc., an AI biotech company. He will also join the Company’s Board of Directors and lead its business development activities.
Martin Hudson will join Oncimmune on 4 September 2023, taking over from Matthew Hall, who has decided to leave after more than five years as Oncimmune’s Chief Financial Officer. Martin Hudson is a CIMA qualified finance professional with over 19 years of international experience in engineering and service companies, including more than seven years with the McLaren Group and over four years at Williams Advanced Engineering. He will head the Company’s finance function and support the new CEO.
In addition, Andrew Unitt will step down as an Independent Non-Executive Director of the Company and as Chair of the Audit Committee on 30 September 2023, after more than nine years with Oncimmune. The Company has started a search for a new Independent Non-Executive Director and Chair of the Audit Committee.
Alistair Macdonald, Oncimmune’s Chairman, said that he was grateful to Andrew and Matthew for their service and welcomed Martin Gouldstone and Martin Hudson to the leadership team. He said that Oncimmune was now ready to start FY2024 with the right leadership and resources to deliver on its plan for growth, based on its strong IP portfolio, its master services agreements with major pharma companies and its long term relationship with Freenome, Inc.
Matthew Hall, Oncimmune’s outgoing CFO, said that he was proud of the Company’s transformation from a diagnostic company to a pharma services business and wished the new management team every success.
Martin Gouldstone, Oncimmune’s incoming CEO, said that he was excited to join Oncimmune and to leverage its leading position in autoantibody profiling to create value for its customers and shareholders. He said that he looked forward to working with Martin Hudson and the rest of the team to grow the business.
Oncimmune Holdings signs agreements with Roche and Cedars-Sinai